Pharmacokinetics of MHAA4549A, an Anti-Influenza A Monoclonal Antibody, in Healthy Subjects Challenged with Influenza A Virus in a Phase IIa Randomized Trial
- 340 Downloads
Background and Objectives
MHAA4549A, a human anti-influenza immunoglobulin (Ig) G1 monoclonal antibody, is being developed to treat patients hospitalized for influenza A infection. This study examined the pharmacokinetics (PKs) of MHAA4549A in a phase IIa, randomized, double-blind, dose-ranging trial in healthy volunteers challenged with influenza A virus.
Serum PK data were collected from 60 subjects in three single-dose groups (400, 1200, or 3600 mg) who received MHAA4549A intravenously 24–36 h after inoculation with the influenza A virus. Nasopharyngeal swab MHAA4549A concentration data were collected on days 1–8, and all subjects, including the placebo group, received 75 mg oseltamivir twice daily from days 7 to 11. Plasma samples were collected 4 h postdose on day 8 for oseltamivir and its active metabolite oseltamivir carboxylate (OC) (all subjects, n = 100), including subjects treated with oseltamivir alone and placebo. Noncompartmental analysis was performed for both nasal and serum PKs.
MHAA4549A showed dose-proportional serum PKs with a long terminal half-life (approximately 21.9–24.6 days) and slow clearance (approximately 152–240 mL/day); however, nasopharyngeal swab PKs were not dose proportional. No differences in mean plasma concentrations of oseltamivir and OC at 4 h postdose on day 8 were observed between the MHAA4549A treatment and placebo groups. No subjects who received MHAA4549A developed anti-drug antibodies.
MHAA4549A serum PKs were consistent with that of a human IgG1antibody without known endogenous targets. MHAA4549A showed nonlinear PKs in nasopharyngeal swab samples, which will guide future dose selection to achieve the high drug concentrations needed at the site of action for efficacy. These data demonstrate no PK interactions between MHAA4549A and oseltamivir, and support flat dosing.
ClinicalTrials.gov identifier, NCT01980966.
Compliance with Ethical Standards
Conflict of interest
Michael A. Derby is a former employee of, and Rong Deng, Ai Ping Lee, Mauricio Maia, Jeremy J. Lim, Tracy Burgess, Priscilla Horn, Elizabeth Newton, Jorge A. Tavel, and William D. Hanley are current employees of Genentech, Inc., a subsidiary of the Roche Group. All authors own Roche stock.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
This study was funded by Genentech, Inc. Anshin BioSolutions and Deborah Solymar (Genentech, Inc.) provided assistance with manuscript editing and writing and were funded by Genentech, Inc.
Informed consent was obtained from all individual participants included in this study.
- 1.World Health Organization. Influenza (Seasonal). Geneva: World Health Organization; 2014. http://www.who.int/mediacentre/factsheets/fs211/en/. Accessed 9 Oct 2016.
- 12.de Jong JC, Beyer WE, Palache AM, Rimmelzwaan GF, Osterhaus AD. Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly. J Med Virol. 2000;61:94–9.CrossRefPubMedGoogle Scholar
- 21.Kamen L, Kho E, Lin YL, Chung S. Anti-influenza antibody MHAA4549A induces ADCC in influenza-infected cells. Presented at the Keystone Symposium on Molecular and Cellular Biology: Antibodies as Drugs (X2). Whistler; 2016 (6–10 March 2016).Google Scholar
- 22.Lim JJ, Deng R, Derby MA, Larouche R, Horn P, Anderson M, et al. Two phase 1, randomized, double-blind, placebo-controlled, single ascending-dose studies to investigate the safety, tolerability, and pharmacokinetics of an anti-influenza a monoclonal antibody, MHAA4549A, in healthy volunteers. Antimicrob Agents Chemother. 2016;60:5437–44.CrossRefPubMedPubMedCentralGoogle Scholar
- 23.McBride JM, Rosenberger C, Tavel JA, Deng R, Derby MA, Burgess T, et al. Clinical safety and efficacy of MHAA4549A, a novel monoclonal antibodyfor the treatment of severe influenza a: results of a randomized, double-blind, placebo controlled clinical trial [poster No. 20161]. Presented at the Keystone Symposium on Molecular and Cellular Biology: Viral Immunity. Breckenridge; 2015 (11–16 Jan 2015).Google Scholar
- 31.Gupta P, Kamath AV, Park S, Chiu H, Lutman J, Maia M, et al. Preclinical pharmacokinetics of MHAA4549A, a human monoclonal antibody to influenza A virus, and the prediction of its efficacious clinical dose for the treatment of patients hospitalized with influenza A. MAbs. 2016;8:991–7.CrossRefPubMedPubMedCentralGoogle Scholar
- 33.Shelton MJ, Lovern M, Ng-Cashin J, Jones L, Gould E, Gauvin J, et al. Zanamivir pharmacokinetics and pulmonary penetration into epithelial lining fluid following intravenous or oral inhaled administration to healthy adult subjects. Antimicrob Agents Chemother. 2011;55:5178–84.CrossRefPubMedPubMedCentralGoogle Scholar
- 34.Wollacott AM, Boni MF, Szretter KJ, Sloan SE, Yousofshahi M, Viswanathan K, et al. Safety and upper respiratory pharmacokinetics of the hemagglutinin stalk-binding antibody VIS410 support treatment and prophylaxis based on population modeling of seasonal influenza A outbreaks. EBioMedicine. 2016;5:147–55.CrossRefPubMedPubMedCentralGoogle Scholar
- 37.Patel K, Kirkpatrick C, Stroh M, Smith P, Deng R. Population pharmacokinetic/pharmacodynamic (PK/PD) modeling of MHAA4549A, an anti-influenza A monoclonal antibody in healthy subjects challenged with influenza A virus [poster no.A-053]. In: Presented at the 55th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Annual Meeting. San Diego; 2015. http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=066fe91c-1dff-48d2-a97e-9d682ce3a71c&cKey=e5865157-b5ac-4d2a-b813-d30a149af1e5&mKey=7a574a80-eab1-4b50-b343-4695df14907e. Accessed 1 Oct 2016 (17–21 Sep 2015).
- 43.US FDA. Guidance for Industry. Influenza: developing drugs for treatment and/or prophylaxis; 2011. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm091219.pdf. Accessed 30 Sep 2016.